Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
This move could cost $299 million a year for Indian pharma players All generic pharmaceutical companies, including Ranbaxy Laboratories, Cipla, Dr Reddy’s Laboratories, Lupin, Glenmark and Torrent Pharma, might soon have to pay a fee to the US drug regulator when they seek its permission to sell their products there. …
Leading pharma companies including GlaxoSmithkline, Pfizer and Ranbaxy sell commonly used drugs at a rate 10 times the cost of production, a study by the Corporate Affairs Ministry has found. A study by the Cost Audit branch of the MCA found drugs like Calpol manufactured by Glaxosmithkline, Corex Cough Syrup …
JAIPUR: Ten investment proposals worth Rs 9,800 crore will be tabled for approval by the state Cabinet committee in a meeting scheduled on Wednesday. If cleared, these companies, ranging form automobiles to automatic teller machines, cements and pharmaceuticals, will open their manufacturing units in the state. The proposals include Brazilian …
Among the southern states, death toll highest in Karnataka As many as 320 people in Karnataka have lost their lives to H1N1 (swine flu) from the time it was first detected in the country in May 2009. Accounting for 12 per cent of H1N1 deaths in the country, Karnataka has …
Move aimed at ending regulatory uncertainty that is holding up clearances of proposals KHOMBA SINGH NEW DELHI The government has formed an inter-ministerial panel for finalising guidelines for allowing MNCs to buy equity stakes in Indian drug companies, as it seeks to end the regulatory uncertainty that is holding up …
The government has initiated a process to reduce Indian drug industry’s growing dependence on China for raw materials, including the critical penicillin, which is needed to manufacture most of the anti-infective drugs. An industry executive told ET that the Organisation of Pharmaceutical Producers of India (OPPI) has submitted a list …
The World Health Organisation (WHO) has put in place a mechanism to define counterfeit medical products. The set of definitions of sub-standard, spurious, falsely labelled, falsified and counterfeit products will be globally accepted and help to bring about uniformity in identifying such drugs, without interrupting worldwide supplies. The decision to …
The current drug discovery paradigm in the West is constrained in what it can do, primarily due to the funding model. Here we envisage a hypothetical non-governmental, non-profit organization called the Centre for Affordable Medicine. By sourcing innovation from a network of academic and corporate partners, and working primarily in …
Glenmark Pharmaceuticals is set to enter the final stage of clinical trials for its new drug, Revamilast, across several countries this year. It is meant for treatment of inflammatory disorders like asthma and rheumatoid arthritis. Glenmark may soon seek approval for Phase-III trials in the US, UK and India. “Glenmark …
New Delhi Commerce and industry minister Anand Sharma has mooted a new formula to the group of ministers (GoM) on pharma pricing to keep prices of essential medicines in check. Sharma recommended that the weighted average price of all drug brands that have more than 5% market share in a …
Who will now be held responsible? Whose negligence is all this? And will the guilty face the music? GUWAHATI/ TEZPUR/ MANGALDOI: At least 350 girls in Tezpur and 45 in Mangaldoi fell ill after they were given folic acid tablets under a National Rural Health Mission (NRHM) scheme in Sonitpur …
A third of malaria drugs used around the world to keep the spread of the disease at bay are counterfeit, recent data has suggested. According to a study published in the reputed journal the Lancet, around 7 per cent of the drugs tested in India was found to be of …
Escalating costs of commonly used drugs across the country has consumers complaining about health care slowly but surely becoming unaffordable. With costs of drugs used by heart patients, diabetics and those used by persons with high blood pressure and cholesterol levels registering a upward trend, drug market watchers state that …
New Delhi Congress MP Jyoti Mirdha on Friday urged the group of ministers on pharma pricing, headed by Union agriculture minister Sharad Pawar, to extend the regime of price control to all the drugs available in the retail market. Mirdha argued that profits earned by pharma companies were primarily used …
Less than 2 p.c. of global trials are conducted in India With India being home to 16 per cent of global population and 20 per cent of global disease burden, it (country) is gradually transforming into a clinical research destination for pharmaceutical companies. But the biggest concern is whether the …
Price control alone will not lower healthcare costs. India will soon have its new drugpricing policy that will determine prices at which pharma companies can sell essential medicines in the retail market. The National Pharmaceutical Pricing Policy, 2011, seeks to evolve a formula to fix the maximum retail prices of …
The Group of Ministers (GoM), headed by Agriculture Minister Sharad Pawar, to formulate a comprehensive pharmaceutical policy aimed at making essential drugs more affordable to the common man, on Monday, met leading lights of the pharmaceutical industry to elicit their views on the issue. The GoM is mainly examining the …
Blockbuster anti-cancer drug Glivec costs $7,367 for a month’s dosage Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multibillion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs’ claims of cheap access and affordability for …
Drug maker Lupin Ltd is expected to soon launch its generic version of the anti-HIV drug, Combivir, in the United States. The move was likely to lend a significant upside to the Mumbai-based company’s bottom line in the forthcoming quarters, a source said. Lupin’s drug, a combination of lamividine and …
